A global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients has broad expertise in development sciences, delivery technologies, and multi-modality manufacturing. The firm is a preferred partner for personalized medicines, blockbuster drugs and consumer health brand extensions. The firm has launched a joint venture investment fund to invest strategically in early-stage startups and platforms. By investing in new technologies, partnering with innovators through co-development and in-licensing, across the academic and industry, the firm helps to bring disruptive innovation to the market. The firm invests globally but has primarily partnered with companies in North America and Europe to date.
The firm invests in technology-enabled platform life sciences companies that are relevant to its science and technology and corporate innovation initiatives. Illustrative potential investments include next-generation biomanufacturing platforms, drug delivery platforms, drug-device combinations, cell-line engineering, mAb discovery, development tools, and inputs. The firm will consider investing in companies advancing therapeutic assets if they are also developing platforms technologies.
The firm can lead or co-invest, and while it considers a board seat a plus, it is not a requirement after investing. The firm values the experience of serial entrepreneurs when partnering and focuses on strategic and deeper relationships.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment